Celltrion announced on the 25th that it has completed the launch of 'Omriclo (75mg/150mg, omalizumab)', developed as a treatment for chronic idiopathic urticaria, in major European countries including Germany, Spain, the UK, and France. This is expected to accelerate its penetration into major European markets.

Omriclo is the 'First Mover' product that received approval from the European Medicines Agency (EMA) as the first omalizumab biosimilar in May last year. Starting with Norway in Northern Europe, it is evaluated to have met the conditions for market preemption through its launch in major European countries.

Particularly, with its launch in the Netherlands, where the EMA headquarters is located, and successful bid achievements, early market preemption results are becoming visible. Celltrion's Dutch subsidiary succeeded in winning bids from multiple hospital groups. It is commencing product supply sequentially. The supply volume won in this bid corresponds to about 70% of the entire omalizumab market in the Netherlands. This demonstrates the consistent competitiveness of Celltrion's products in Europe. Celltrion is enhancing its market dominance by deploying a tailored direct sales strategy considering the market environment of each country. In countries like Spain and the UK, which are bid-centered, it is actively leveraging the absence of competing biosimilar products to gain bid superiority, while in sales-based markets like Germany, it is conducting customized marketing activities specialized for major supply channels such as healthcare providers and pharmacies. Celltrion analyzed that as the sales strategy proves effective, the speed of market entry is accelerating, with pre-orders for Omriclo being placed even before bid commencement in some countries.

Ha Tae-hoon, Head of Celltrion's European Headquarters, stated, “Omriclo is the first mover product among omalizumab biosimilars to be launched in the European market, expanding its market influence based on quality, efficacy, and safety data,” and added, “We will continue to expand the countries where Omriclo is launched, based on the trust in the Celltrion brand established through our direct sales system in Europe, to enhance treatment accessibility for more patients.”

Celltrion's Omriclo is used to treat chronic idiopathic urticaria, asthma, and other conditions. The original drug, Xolair, recorded global sales of approximately KRW 6,499.2 billion last year.

Popular News